Stock HRMY HARMONY BIOSCIENCES HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
30.14 USD -3.64% Intraday chart for Harmony Biosciences Holdings, Inc. -4.53% -6.69%
04-30 Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise MT
04-30 Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise
MT
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.
CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q1 EPS $0.88, vs. Street Est of $0.78
MT
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024
CI
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy
MT
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome
CI
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued
MT
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.
CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q4 EPS $0.73, vs. Street Est of $0.91
MT
Harmony Biosciences Holdings, Inc. Provides Revenue Guidance for the Year 2024
CI
North American Morning Briefing : Nvidia Ignites -2-
DJ
Harmony Biosciences Says FDA Grants Priority Review for Wakix Supplemental New Drug Application
MT
U.S. Food and Drug Administration Grants Priority Review to Harmony Biosciences' Application for WAKIX® in Pediatric Narcolepsy
CI
Harmony Biosciences' Pitolisant Gets FDA's Orphan Drug Designation for Prader-Willi Syndrome
MT
Harmony Biosciences Gets FDA Orphan Designation for Pitolisant in Prader-Willi Syndrome
DJ
Harmony Biosciences Reports Higher Preliminary Q4 Revenue; Sets 2024 Revenue Outlook
MT
Harmony Biosciences Holdings, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year 2023 and for the Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HRMY Stock
  4. News Harmony Biosciences Holdings, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW